Swedish Cancer Society   Report issue

Foundation Phase 1 Phase 2 Phase 3
Founded: Stockholm Sweden (1951)

Organization Overview

First Clinical Trial
2001
NCT03888677
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Swedish Cancer Society

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 3)

Carcinoma, Ovarian Epithelial (Phase 1)

Leukemia, B-Cell (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Ovarian Neoplasms (Phase 1)

Rectal Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 10